Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
Open Access
- 3 October 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 95 (8), 966-973
- https://doi.org/10.1038/sj.bjc.6603383
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of lifeThorax, 2004
- Direct Treatment Costs for Patients with Lung Cancer from First Recurrence to Death in FrancePharmacoEconomics, 2003
- Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancerLung Cancer, 2002
- Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trialEuropean Journal of Cancer, 1998
- 180 Additional treatment does not improve the survival of locally advanced or metastatic NSCLC patients who responded after two courses of cisplatin (C), vindesin (V), mitomycin (M) chemotherapyLung Cancer, 1997
- Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II studyEuropean Journal of Cancer, 1997
- Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapyEuropean Journal of Cancer, 1995
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trialsEuropean Journal of Cancer, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective studyCancer, 1989